We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002736:SZSEGuosen Securities Co., Ltd. Class A Analysis

Data as of 2026-03-12 - not real-time

CN¥12.25

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Guosen Securities is trading at CNY12.25, comfortably above its short‑term support of CNY11.89 but still below the 20‑day SMA of 12.33, indicating limited upside in the near term. The price sits beneath the 50‑day (12.73) and 200‑day (12.95) moving averages, confirming a broader bearish bias. Nevertheless, the MACD histogram has turned positive and the MACD line is marginally above its signal, suggesting a tentative bullish momentum that could test the resistance at CNY12.67. RSI at 45 is neutral, and the increasing volume trend adds credibility to any potential breakout. On the valuation side, the stock’s trailing PE of 10.6 is well under the industry average of 16.6, and the price‑to‑book of 1.29 reflects a modest premium to book value. The DCF‑derived fair value of CNY14.5 implies roughly 18% upside from current levels, while the consensus target of CNY21 suggests a longer‑term upside of over 70%. A dividend yield of 3.69% with a payout ratio of 30% signals a sustainable income stream, supported by strong profit margins (44% net) and a healthy ROE of 10%. The balance sheet shows a high debt‑to‑equity ratio of 207%, yet cash holdings exceed debt, leaving the company net‑cash positive and mitigating immediate solvency concerns. Revenue growth is modest at 2% YoY, but the exceptionally high gross (91.6%) and operating margins (57.8%) highlight the business’s fee‑driven profitability. Volatility of nearly 20% over the past month and a low beta (≈0.2‑0.4) indicate that price swings are pronounced but the stock is relatively insulated from broader market moves. Regulatory risk in China’s financial sector remains elevated, which could constrain earnings or impose capital requirements. Overall, the combination of undervaluation, solid cash flow, and a generous dividend makes the stock attractive for investors willing to bear sector‑specific and regulatory headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near short‑term resistance at CNY12.67
  • MACD histogram turning positive with increasing volume
  • Overall bearish trend indicated by moving averages

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value suggests ~18% upside
  • Sustainable dividend yield of 3.69% with low payout ratio
  • Net‑cash position despite high leverage

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Consensus target price of CNY21 implies >70% upside
  • Strong profit margins and ROE indicating durable earnings power
  • Robust cash generation and dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth102.00%
Profit Margin44.60%
P/E Ratio10.6
ROE10.32%
ROA2.39%
Debt/Equity207.05
P/B Ratio1.3
Op. Cash FlowCN¥3.0B
Industry P/E16.6

Technical Analysis

TrendBearish
RSI45.7
SupportCN¥11.89
ResistanceCN¥12.67
MA 20CN¥12.33
MA 50CN¥12.73
MA 200CN¥12.95
MACDBullish
VolumeIncreasing
Fear & Greed Index76.77

Valuation

Fair ValueCN¥14.52
Target PriceCN¥21.00
Upside/Downside71.43%
GradeUndervalued
TypeBlend
Dividend Yield3.69%

Risk Assessment

Beta0.21
Volatility19.70%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.